OKYO Pharma Limited Change of Delisting Date to 22 May 2023 (0191Z)
May 11 2023 - 1:00AM
UK Regulatory
TIDMOKYO
RNS Number : 0191Z
OKYO Pharma Limited
11 May 2023
11 May 2023
OKYO Pharma Limited
("OKYO" or "Company")
Change of Delisting Date to 22 May 2023
The board of directors of OKYO Pharma Limited (LSE: OKYO;
NASDAQ: OKYO), announces that it has delayed the date on which the
cancellation of its ordinary shares of no par value each ("Ordinary
Shares") from listing on the standard segment of the FCA's Official
List and trading on the main market for listed securities of the
LSE ("Main Market") ("Delisting") will take place until Monday, 22
May 2023. This is a facilitate late transfers of certificated
positions into CREST ahead of the Delisting.
The Delisting will have no impact on the Company's American
Depositary Shares ("ADSs") (each currently representing 65 Ordinary
Shares) which are traded on Nasdaq.
The securities to which the Delisting relates are the Ordinary
Shares of OKYO Pharma Limited with ISIN GG00BD3FV870. Following the
Delisting, it will no longer be possible to trade the Ordinary
Shares on the Main Market or any other market of the LSE.
Information for holders through CREST
Following the share consolidation (which will take place on the
Delisting Date), holders of the Company's ordinary shares in CREST
will receive a CDI (a CREST depositary interest issued by
Euroclear) into their CREST account, with each CDI representing one
new ordinary share. The CDIs can be exchanged for the new ordinary
shares within the CREST system. Full instructions will be posted to
the Company's website when Delisting has occurred.
Information for holders in certificated form
For persons who currently hold Ordinary Shares in certificated
form, these shareholders will receive a "DRS Statement" from the
Company's US transfer agent, by post. The DRS Statement will
explain how to dematerialise the underlying shares into a trading
account. ANY SHAREHOLDERS WHO CURRENTLY HOLD ORDINARY SHARES IN
CERTIFICATED FORM ARE URGED TO SPEAK TO THEIR STOCKBROKER OR SHARE
DEALING PLATFORM AND TO MOVE THEIR CERTIFICATED ORDINARY SHARES
INTO CREST PRIOR TO THE DELISTING DATE. THIS WILL SUBSTANTIALLY
SIMPLIFY THE PROCESS FOR RECEIVING NASDAQ TRADED ORDINARY SHARES.
ANY HOLDER OF CERTIFICATED ORDINARY SHARES SHOULD ALSO ENSURE THAT
THE COMPANY'S REGISTRAR HAS FULLY UP-TO-DATE INFORMATION AS TO
THEIR CURRENT ADDRESS AS DRS STATEMENTS CANNOT EASILY BE
REISSUED.
Enquiries:
Gary S. Jacob, Chief
OKYO Pharma Limited Executive Officer +44 (0)20 7495 2379
Investor Relations Paul Spencer +44 (0)20 7495 2379
Optiva Securities
Limited
(Broker) Robert Emmet +44 (0)20 3981 4173
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCGPUWCAUPWGRU
(END) Dow Jones Newswires
May 11, 2023 02:00 ET (06:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2023 to Apr 2024